功能MRI定量技术在前列腺癌中的应用研究进展

朱蓉; 王关顺; 张娅; 李瑞乾; 杨银蕊; 沈婧; 顾尚尉

doi:10.16766/j.cnki.issn.1674-4152.003808

功能MRI定量技术在前列腺癌中的应用研究进展

doi: 10.16766/j.cnki.issn.1674-4152.003808

北京大学肿瘤医院云南医院(云南省肿瘤医院)放射科，云南昆明 650100

基金项目:

云南省科技厅计划项目 202301AY07001-093

详细信息

通讯作者:
王关顺，E-mail：wgsh602@163.com

中图分类号: R737.25 R445.2
计量
- 文章访问数: 18
- HTML全文浏览量: 11
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-02-23
- 网络出版日期: 2025-01-20

Research progress of quantitative functional magnetic resonance imaging in prostate cancer

Department of Radiology, Yunnan Hospital of Peking University Cancer Hospital, Kunming, Yunnan 650100, China

摘要

摘要: 目前临床上主要通过前列腺特异性抗原(PSA)检测、MRI检查及超声引导下穿刺活检来诊断前列腺癌(PCa)。PSA是PCa的特异性肿瘤标志物，但前列腺增生、前列腺炎、膀胱镜检等PSA亦会升高，易出现假阳性结果。MRI是诊断的主要影像学检查技术，尤其是功能MRI在PCa的诊断中具有重要价值。目前基于扩散加权成像(DWI)、T₂WI、动态对比增强(DCE)形成的前列腺影像报告和数据系统(PI-RADS)已广泛应用于PCa的临床诊断中。但是对于各序列的评分仍然依赖影像科医生的主观性经验，尤其是PI-RADS 3分病灶不能确定其良恶性，也导致对该类病灶穿刺建议的不确定性。另外，不同危险分层PCa的预后、治疗方案的选择不同。PCa侵袭性通常通过Gleason评分(GS)反映。GS为最常见的肿瘤组织学Gleason分级数加上次常见的组织学Gleason分级数之和，Gleason分级根据细胞的分化程度分为1~5级，分级越高，细胞分化程度越差，预后越差。近年来，体素内不相干运动扩散加权成像、扩散峰度成像、动态增强磁共振成像、酰胺质子转移成像等多种功能MRI新技术不断发展，其定量参数可对前列腺病灶的细胞结构及细胞扩散、微循环灌注及血管生成、分子代谢变化等精准量化，有助于提高前列腺癌的诊断准确性，并具有预测肿瘤侵袭性的潜力，这将为PCa的正确诊断提供更多有价值的客观证据。本文综述以上功能MRI定量新技术在PCa诊断中的研究进展。
- 前列腺癌 /
- 扩散加权成像 /
- 动态增强磁共振成像 /
- 酰胺质子转移成像 /
- 体素内不相干运动 /
- 扩散峰度成像
Abstract: Prostate specific antigen (PSA), MRI examination and ultrasound-guided puncture biopsy are mainly used to diagnose prostate cancer (PCa). PSA is a specific tumor marker for PCa, but PSA is also elevated in prostate hyperplasia, prostatitis, cystoscopy, etc., which is prone to false-positive results. MRI is the main imaging technique for diagnosis, especially functional MRI plays an important value in the diagnosis of PCa. At present, the prostate imaging reporting and data system (PI-RADS) based on diffusion weighted imaging, diffusion weighted imaging (DWI), DCE and T₂WI has been widely used in the clinical diagnosis of PCa. However, the scoring of each sequence still relies on the subjective experience of the imaging physician, especially the PI-RADS score of 3 lesions cannot be determined as benign or malignant, which also leads to the uncertainty of the recommendation of puncture for such lesions. In addition, the prognosis and choice of treatment options for PCa differ among different risk strata. The aggressiveness of PCa is usually reflected by the Gleason score (GS). GS is the sum of the most common histological Gleason grade of the tumor plus the second most common histological Gleason grade. Gleason grading is divided into 1-5 grades according to the degree of differentiation of the cells, and the higher the grade, the worse the degree of cell differentiation and the worse the prognosis. In recent years, various new functional MRI techniques such as amide proton transfer imaging, intravoxel incoherent motion diffusion weighted imaging, diffusion kurtosis imaging, dynamic enhanced magnetic resonance imaging, etc. have been developed, and their quantitative parameters can accurately quantify the cytoarchitecture of prostate foci and cellular diffusion, microcirculation perfusion and angiogenesis, and molecular metabolism changes, which can help to increase the diagnostic accuracy of prostate cancer and have the potential to predict tumor. It also has the potential to predict tumor aggressiveness, which will provide more valuable objective evidence for the correct diagnosis of PCa. This article summarizes the research progress of the above new functional MRI quantitative techniques in the diagnosis of PCa.
- Prostate cancer /
- Diffusion weighted imaging /
- Dynamic contrast enhanced magnetic resonance imaging /
- Amide proton transfer imaging /
- Intravoxel incoherent motion diffusion imaging /
- Diffusion kurtosis imaging

HTML全文

参考文献(33)

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究, 2021, 48(1): 98-102. LI X, ZENG X Y. Advances in epidemiology of prostate cancer in China[J]. Cancer Res Prev Treat, 2021, 48(1): 98-102.
[3]	MOTTET N, VAN DEN BERGH R C N, BRIERS E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021, 79(2): 243-262. doi: 10.1016/j.eururo.2020.09.042
[4]	黄泽海, 黄晓敏, 陈泽荣, 等. 3D腹腔镜与2D腹腔镜下腹膜外前列腺癌根治术双中心回顾性队列研究[J]. 中华全科医学, 2022, 20(6): 919-922. doi: 10.16766/j.cnki.issn.1674-4152.002487 HANG Z H, HUANG X M, CHEN Z R, et al. Three-dimensional versus two-dimensional imagine systems in extraperitoneal radical prostatectomy for prostate cancer: a bicenter and retrospective cohort study[J]. Chinese Journal of General Practice, 2022, 20(6): 919-922. doi: 10.16766/j.cnki.issn.1674-4152.002487
[5]	刘晓燕, 王宝剑, 张娟, 等. 酰胺质子转移成像原理及其在脑胶质瘤中的研究进展[J]. 磁共振成像, 2022, 13(2): 127-129. LIU X Y, WANG B J, ZHANG J, et al. Principle of amide proton transfer imaging and its research progress in glioma[J]. Chin J Magn Reson Imaging, 2022, 13(2): 127-129.
[6]	PIHLSTRØM N, JIN Y, NENSETH Z, et al. STAMP2 expression mediated by cytokines attenuates their growth-limiting effects in prostate cancer cells[J]. Cancers (Basel), 2021, 13(7): 1579. DOI: 10.3390/cancers13071579.
[7]	YANG L, WANG L, TAN Y C, et al. Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study[J]. Cancer Imaging, 2023, 23(1): 3. DOI: 10.1186/s40644-022-00515-w.
[8]	GUO Z X, QIN X Y, MU R H, et al. Amide proton transfer could provide more accurate lesion characterization in the transition zone of the prostate[J]. J Magn Reson Imaging, 2022, 56(5): 1311-1319. doi: 10.1002/jmri.28204
[9]	胡文君, 刘爱连, 陈丽华, 等. 酰胺质子转移成像联合T₂-mapping鉴别前列腺癌与前列腺增生的价值[J]. 放射学实践, 2022, 37(11): 1416-1421. HU W J, LIU A L, CHEN L H, et al. The value of amide proton transfer imaging combined with T2-mapping for differentiating prostate cancer from benign prostatic hyperplasia[J]. Chin J Magn Reson Imaging, 2022, 37(11): 1416-1421.
[10]	任雪, 刘爱连, 陈丽华, 等. APT联合mDIXON-Quant成像对前列腺癌和前列腺增生的鉴别诊断价值[J]. 放射学实践, 2023, 38(1): 58-64. REN X, LIU A L, CHEN L H, et al. The value of APT combined with mDIXON-Quant imaging in the differential diagnosis of prostate cancer and benign prostatic hyperplasia[J]. Radiol Practice, 2023, 38(1): 58-64.
[11]	YIN H J, WANG D D, YAN R F, et al. Comparison of diffusion kurtosis imaging and amide proton transfer imaging in the diagnosis and risk assessment of prostate cancer[J]. Front Oncol, 2021, 11: 640906. DOI: 10.3389/fonc.2021.640906.
[12]	李茜玮, 陈丽华, 王楠, 等. 初探酰胺质子加权联合mDixon-Quant序列评估前列腺癌骨转移的价值[J]. 中国临床医学影像杂志, 2022, 33(8): 540-545. LI X W, CHEN L H, WANG N, et al. Preliminary study on the application of amide protontransfer-weighted combined with mDixon-Quant imaging in differentiating bone metastasis of prostate cancer[J]. Chin Clin Med Imaging, 2022, 33(8): 540-545.
[13]	张鹏运, 汤芸行, 姜昊洋, 等. 三维酰胺质子转移成像鉴别前列腺癌伴骨转移与不伴骨转移的可行性研究[J]. 磁共振成像, 2022, 13(12): 100-103, 110. ZHANG P Y, TANG Y X, JIANG H Y, et. al. Feasibility study of three-dimensional amide proton transfer imaging in differentiating prostate cancer with and without bone metastasis[J]. Chin J Magn Reson Imaging, 2022, 13(12): 100-103, 110.
[14]	ZABIHZADEH M, FATAHI ASL J, FARZANEGAN Z, et al. Accuracy of magnetic resonance spectroscopy techniques in prostate cancer and prostatitis[J]. Arch Iran Med, 2020, 23(2): 104-112.
[15]	GHOLIZADEH N, GREER P B, SIMPSON J, et al. Diagnosis of transition zone prostate cancer by multiparametric MRI: added value of MR spectroscopic imaging with sLASER volume selection[J]. J Biomed Sci, 2021, 28(1): 54. DOI: 10.1186/s12929-021-00750-6.
[16]	TAVAKOLI A A, HIELSCHER T, BADURA P, et al. Contribution of dynamic contrast-enhanced and diffusion MRI to PI-RADS for detecting clinically significant prostate cancer[J]. Radiology, 2023, 306(1): 186-199.
[17]	SCIALPI M, MARTORANA E, SCALERA G B, et al. Apparent diffusion coefficient and lesion volume to detect prostate cancer[J]. Radiology, 2023, 307(3): e222177. DOI: 10.1148/radiol.222177.
[18]	WEN B H, ZHANG Z X, ZHU J, et al. Apparent diffusion coefficient map-based radiomics features for differential diagnosis of pleomorphic adenomas and warthin tumors from malignant tumors[J]. Front Oncol, 2022, 12: 830496. DOI: 10.3389/fonc.2022.830496.
[19]	SUROV A, MEYER H J, WIENKE A. Correlations between apparent diffusion coefficient and Gleason score in prostate cancer: a systematic review[J]. Eur Urol Oncol, 2020, 3(4): 489-497.
[20]	MANETTA R, PALUMBO P, GIANNERAMO C, et al. Correlation between ADC values and Gleason score in evaluation of prostate cancer: multicentre experience and review of the literature[J]. Gland Surg, 2019, 8(Suppl 3): S216-S222.
[21]	邢朋毅, 宋涛, 王铁功, 等. 基于双参数磁共振成像影像组学机器学习的前列腺癌风险分层[J]. 第二军医大学学报, 2021, 42(3): 233-242. XING P Y, SONG T, WANG T G, et al. Risk stratification of prostate cancer based on biparametric magnetic resonance imaging radiomics machine learning[J]. Academic Journal of Second Military Medical University, 2021, 42(3): 233-242.
[22]	徐嬿, 杨贤卫, 王千里, 等. IVIM-DWI定量分析对扶正消瘀散结方联合内分泌治疗Ⅲ、Ⅳ期前列腺癌疗效的评估研究[J]. 临床放射学杂志, 2022, 41(10): 1926-1930. XU Y, YANG X W, WANG Q L, et al. Quantitative diagnostic value of IVIM-MRI to evaluate the efficacy in Fuzheng Xiaoyu Sanjie combined with endocrine treatment for Ⅲ, Ⅳ stage-prostate cancer[J]. Clinical Radiology, 2022, 41(10): 1926-1930.
[23]	程昊, 李春媚. 前列腺MRI的新技术进展[J]. 中国医学影像学杂志, 2023, 31(4): 418-423. CHENG H, LI C M. Development of new technology of prostate magnetic resonance imaging[J]. Chinese Journal of Medical Imaging, 2023, 31(4): 418-423.
[24]	BEYHAN M, SADE R, KOC E, et al. The evaluation of prostate lesions with IVIM DWI and MR perfusion parameters at 3T MRI[J]. Radiol Med, 2019, 124(2): 87-93.
[25]	YAO W G, LIU J, ZHENG J J, et al. Study on diagnostic value of quantitative parameters of intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) in prostate cancer[J]. Am J Transl Res, 2021, 13(4): 3696-3702.
[26]	郭定波, 曾国飞, 杨华, 等. 体素内不相干运动扩散加权成像在前列腺癌鉴别诊断及Gleason分级中应用的Meta分析[J]. 磁共振成像, 2022, 13(2): 69-74. GUO D B, ZENG G F, YANG H, et al. Intravoxel incoherent motion diffusion-weighted imaging for assessment of the differential diagnosis and Gleason grade in prostate cancer: a meta-analysis[J]. Chin J Magn Reson Imaging, 2022, 13(2): 69-74.
[27]	CHEN Z W, XUE Y N, ZHANG Z, et al. The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone[J]. Eur J Radiol, 2020, 125: 108865. DOI: 10.1016/j.ejrad.2020.108865.
[28]	RIEXINGER A, MARTIN J, WETSCHEREK A, et al. An optimized b-value distribution for triexponential intravoxel incoherent motion (IVIM) in the liver[J]. Magn Reson Med, 2021, 85(4): 2095-2108.
[29]	ABREU-GOMEZ J, LIM C, CRON G O, et al. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers[J]. Abdom Radiol (NY), 2021, 46(9): 4370-4380.
[30]	MICHALLEK F, HUISMAN H, HAMM B, et al. Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study[J]. Eur Radiol, 2022, 32(5): 3236-3247.
[31]	罗拥志, 王习. 动态对比增强磁共振成像联合扩散加权成像对前列腺中央腺体癌的诊断价值[J]. 磁共振成像, 2021, 12(9): 61-64. LUO Y Z, WANG X. Diagnostic value of DCE-MRI combined with DWI for central gland prostate cancer[J]. Chin J Magn Reson Imaging, 2021, 12(9): 61-64.
[32]	李新瑜, 刘晴晴, 李明霞, 等. 高b值表观扩散系数与动态增强磁共振定量参数对移行带前列腺癌的诊断价值[J]. 中国医学影像学杂志, 2023, 31(10): 1096-1100, 1108. LI X Y, LIU Q Q, LI M X, et al. Diagnostic value of high b value apparent diffusion coefficient and dynamic contrast enhanced magnetic resonance quantitative parameters in transitional zone prostate cancer[J]. Chinese Journal of Medical Imaging, 2023, 31(10): 1096-1100, 1108.
[33]	MICHALLEK F, HUISMAN H, HAMM B, et al. Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study[J]. Eur Radiol, 2022, 32(4): 2372-2383.